ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 315

Pediatric Lupus Nephritis: Micrornas – Macro Inflammation

Patrícia Costa Reis1, Pierre Russo2 and Kathleen E. Sullivan3, 1Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

New biomarkers to guide clinical management of lupus nephritis (LN) patients are highly desirable, since the histopathologic classification currently in use is an unreliable predictor of treatment response and disease outcome.  MicroRNAs have emerged as a new class of biomarkers in several rheumatic diseases, but their role in LN is still unclear. These noncoding RNAs have a post-transcriptional regulatory effect, playing a key role in fundamental cellular processes and influencing immunologic function, especially in the maintenance of immunological tolerance. Perturbations in the microRNA expression patterns can, therefore, lead to pathological conditions, including autoimmune diseases, like systemic lupus erythematosus (SLE).

MicroRNA studies performed on serum, urine and peripheral blood mononuclear cells have revealed distinct profiles in SLE patients. Further studies are thus necessary to identify a specific LN microRNA signature, which will illuminate SLE pathogenesis and may lead to novel LN biomarkers.

The main aim of this study is to identify the microRNA signature in kidneys of children with LN. The ultimate goal is to find microRNAs associated with disease activity and prognosis that may guide clinical practice.

Methods:

Paraffin-embedded tissue samples from children with LN, kidney biopsies performed on kidney donors, and post-streptococcal glomerulonephritis were used for microRNA extraction with Quiagen™ miRNeasy kit. Direct digital detection of microRNAs, through molecular barcodes, was performed with the nCounter® human miRNA assay kit. 

Results:

The microRNA signature can clearly differentiate samples from normal kidneys of those affected with LN. From over 700 human microRNAs analyzed, miR-26a and miR-30b were identified as being associated with pediatric LN. A significant decrease in the expression of these microRNAs was found in LN class IV, when compared to normal tissue, post-streptococcal glomerulonephritis, LN class III or LN class V. 

Conclusion:

An altered microRNA signature can lead to the dysregulation of gene expression and broadly alter cell behavior. The study of microRNAs can, therefore, improve our understanding of the pathogenesis of several diseases. With this project, miR-26a and miR-30b were identified for the first time as components of the microRNA signature in kidneys of children with LN. These microRNAs are predicted to regulate the expression of genes that interfere with cell cycle, apoptosis and immune regulation, including IL18R1, which has been implicated in the pathogenesis of nephritis and tissue inflammation and HDAC9, which acts as an epigenetic switch in effector T cell-mediated systemic autoimmunity.  This study has provided new insights for LN pathogenesis and for the development of new biomarkers.


Disclosure:

P. Costa Reis,
None;

P. Russo,
None;

K. E. Sullivan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pediatric-lupus-nephritis-micrornas-macro-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology